Approval · Notice of Compliance 21889 · 2019
MENVEO: Notice of Compliance 21889
Issued February 25, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21889
- Date
- February 25, 2019
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MENVEO | Not yet assigned | — |
Medicinal ingredients
- MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTERIAE CRM 197 10 MCG per 0.5ML
- MENINGOCOCCAL GROUP C OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTERIAE CRM 197 5 MCG per 0.5ML
- MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTERIAE CRM 197 5 MCG per 0.5ML
- MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTERIAE CRM 197 5 MCG per 0.5ML